In January 2025, the U.S. Food and Drug Administration approved suzetrigine for certain types of moderate to severe acute pain in adults. The drug introduces a new class of non-opioid analgesics and expands the options available after an injury or surgery.
Blocking the signal before it reaches the brain
Marketed in the United States as Journavx, suzetrigine targets a sodium channel called NaV1.8 in the peripheral nervous system. In simple terms, it reduces transmission of the pain signal from the injured area before the signal reaches the brain. Its action therefore differs from that of opioids.
This distinction matters because opioids can cause dependence, slowed breathing and other serious adverse effects. However, a non-opioid treatment is not automatically free of risk. It must be prescribed according to the clinical situation, other medications and the patient’s health.
Two controlled trials of postoperative pain
The Food and Drug Administration relied on two randomized trials conducted after abdominoplasty and bunion surgery. In both studies, suzetrigine reduced pain more than a placebo. Participants could receive ibuprofen as rescue medication when pain relief was insufficient.
The main safety data covered 874 people in the controlled trials, supplemented by an open-label study of 256 participants. The most common adverse effects included itching, muscle spasms, increased levels of a muscle enzyme and skin rashes.
One more option, not a universal replacement
The authorization covers acute pain in U.S. adults. It does not show that the drug is appropriate for every type of pain or superior to every existing treatment. Some interactions are important: it should not be combined with strong CYP3A inhibitors, and grapefruit should be avoided during treatment.
The advance lies in the arrival of a new mechanism after decades with few new classes of analgesics. Real-world data will help clarify its role, cost and comparative benefits. Treatment decisions should always be made with a health professional.
The approval may also stimulate research into other kinds of pain and molecules that target peripheral nerves. For patients, its real value will be measured in routine care: quality of relief, tolerability, access and any reduction in opioid use. These answers will require independent comparisons and longer-term data. Suzetrigine is therefore an open door rather than a final conclusion. It shows that a new biological pathway against pain is possible while maintaining the usual requirements for caution, monitoring and shared medical decision-making. Health authorities in other countries must conduct their own evaluations before approving it.
Sources
- Food and Drug Administration, FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain, January 30, 2025.
- Rahul B. Ganatra, MD, MPH, “Suzetrigine, a New Nonopioid Pain Medication, Gains U.S. FDA Approval,” NEJM Clinician, April 8, 2025.
Photo credit: Julia Koblitz and Trnava University / Unsplash. Illustrative images.
Article written in part with the help of AI.
